ExodusPoint Capital Management LP Purchases New Shares in Moderna, Inc. (NASDAQ:MRNA)

ExodusPoint Capital Management LP bought a new position in Moderna, Inc. (NASDAQ:MRNA - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 87,970 shares of the company's stock, valued at approximately $3,658,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Allworth Financial LP grew its position in Moderna by 17.3% during the 4th quarter. Allworth Financial LP now owns 1,901 shares of the company's stock valued at $73,000 after purchasing an additional 281 shares during the last quarter. Howard Capital Management Inc. grew its holdings in shares of Moderna by 3.1% during the fourth quarter. Howard Capital Management Inc. now owns 9,994 shares of the company's stock valued at $416,000 after buying an additional 297 shares during the last quarter. Commonwealth Equity Services LLC increased its position in shares of Moderna by 0.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company's stock valued at $3,099,000 after acquiring an additional 345 shares in the last quarter. Larson Financial Group LLC raised its holdings in Moderna by 39.1% in the 4th quarter. Larson Financial Group LLC now owns 1,266 shares of the company's stock worth $53,000 after acquiring an additional 356 shares during the last quarter. Finally, New Insight Wealth Advisors lifted its position in Moderna by 4.4% in the 4th quarter. New Insight Wealth Advisors now owns 8,545 shares of the company's stock valued at $355,000 after acquiring an additional 358 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Remove Ads

Moderna Trading Up 6.9 %

Shares of NASDAQ:MRNA traded up $1.70 during mid-day trading on Friday, reaching $26.20. The stock had a trading volume of 10,999,018 shares, compared to its average volume of 7,181,061. The business's 50 day moving average price is $31.56 and its 200 day moving average price is $41.01. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $170.47. The company has a market cap of $10.13 billion, a P/E ratio of -2.82 and a beta of 2.23.

Wall Street Analyst Weigh In

Several research firms recently commented on MRNA. The Goldman Sachs Group cut Moderna from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $99.00 to $51.00 in a research report on Wednesday, January 29th. Berenberg Bank increased their price objective on shares of Moderna from $33.00 to $42.00 and gave the stock a "hold" rating in a research note on Thursday, January 16th. JPMorgan Chase & Co. cut their target price on shares of Moderna from $40.00 to $33.00 and set an "underweight" rating for the company in a research report on Friday, March 21st. Bank of America decreased their price target on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research report on Tuesday, February 11th. Finally, Argus downgraded shares of Moderna from a "buy" rating to a "hold" rating in a research report on Wednesday, December 18th. Four analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $58.70.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.